Celltrion

- Early performance demonstrated with national tender wins in Norway and Denmark… Secured 35% share of the IV market in the Netherlands

- The world’s first and only infliximab liquid formulation… Patent registrations completed across most European countries including the EU5

- Continued field-friendly marketing activities through formulation innovation reflecting clinical needs… Enhancing brand value

- The world’s first and only full infliximab portfolio of IV and SC formulations… “Will continue innovation in biosimilar products”

[March 11, 2026, KST] Celltrion today announced the European launch of the liquid formulation of Remsima (infliximab), strengthening its leadership in the infliximab market. The infliximab liquid formulation is uniquely held by Celltrion globally and is supported by registered patents. As a newly introduced formulation reflecting clinical needs, it is expected to further reinforce Remsima’s influence through enhanced product competitiveness and expanded market impact.

Celltrion’s Nordic affiliate achieved early success by securing contracts with the Remsima intravenous (IV) liquid formulation in infliximab national tenders held in Denmark and Norway. Following the European approval of the Remsima IV liquid formulation in November last year, the local affiliate had prepared in advance to ensure product distribution through key national tenders. As a result, sales in Norway began immediately after the tender award, with supply planned through January 2028. Through this, the product is expected to secure approximately 35% share of the infliximab IV market in Norway.

The Remsima liquid formulation expands treatment options by reflecting clinical needs, alongside the existing Remsima IV (100 mg lyophilized formulation) and Remsima SC. In European clinical settings, there has been continuous demand for a multi-dose liquid formulation that enables more efficient storage and management while reducing the complexity of the preparation process. Reflecting these needs, Celltrion has introduced the Remsima 350 mg liquid formulation, while continuing to strengthen field-focused sales and marketing activities.

With the field-friendly Remsima liquid formulation, healthcare institutions are expected to benefit from administrative and cost efficiencies, further strengthening the competitiveness of the Remsima portfolio. Compared with the lyophilized formulation, the liquid formulation can reduce preparation time by approximately 50%, while lowering labor and consumable costs by around 20% during drug preparation.

In addition, storage space and related storage costs can be reduced by up to 70%, generating strong interest across Europe from the early stage of launch. The recent national tender award in Norway also reflects recognition of these advantages and is expected to serve as a new competitive strength for Remsima in Europe, where tender markets represent a significant portion of demand.

Celltrion has also filed patents for the Remsima liquid formulation and has completed patent registrations in most European countries, including the EU5 markets such as the UK, Germany and France. As Remsima is the only infliximab product available in a liquid formulation, its differentiated competitiveness is expected to further strengthen its influence in the infliximab market.

Following the development and commercialization of the world’s first infliximab SC formulation, Celltrion has now secured the IV liquid formulation, becoming the only company globally to establish a full portfolio of infliximab IV (lyophilized and liquid) and SC formulations. Based on this, the company aims to further strengthen brand trust in Remsima in the infliximab market, expand prescriptions across both Remsima IV and SC, and enhance profitability. In addition, Celltrion plans to continue product innovation reflecting clinical needs while reinforcing its differentiated corporate image with unique competitiveness in the biosimilar market.

Starting with the Nordic region, Celltrion plans to expand the launch of the Remsima liquid formulation across Europe this year, including France, the Netherlands and the Czech Republic, further strengthening its leadership in the infliximab market. According to pharmaceutical market research firm IQVIA, the Remsima portfolio (IV and SC) maintained the No.1 position in infliximab prescriptions in Europe with a 68% market share as of Q3 last year. Based on the strengthened Remsima portfolio with a full formulation lineup, Celltrion plans to continue strengthening its market position while addressing diverse clinical needs.

“As trust in Celltrion continues to build in the European biosimilar market, the Remsima liquid formulation reflects clinical needs and has demonstrated its competitiveness by securing tender wins immediately after launch," said Seung-doo Baek, Head of Celltrion’s Nordic affiliate. "Going forward, we will continue field-focused sales and marketing activities to provide better treatment options for patients and healthcare professionals in Europe while further expanding prescriptions.”